How long does combined hormonal therapy suppress AMH levels in women with endometriomas? Results from an exploratory analysis of a clinical trial.
Lower Anti-Müllerian hormone (AMH) levels have been observed in women with ovarian endometriomas (OMA) undergoing combined hormonal contraceptive (CHC) therapy. However, the extent and timing of AMH recovery after CHC …
Aortic mural thrombosis with bilateral renal infarction in a woman taking dienogest for adenomyosis: A case report and literature review.
We presented a rare case of aortic mural thrombosis with bilateral renal infarction in a woman taking dienogest for adenomyosis. The objective is to highlight the possible risk of thrombosis …
Impact of endometrioma management strategies on ovarian reserve over the follow-up period, a prospective longitudinal study.
The effects of current treatment options for endometrioma on ovarian reserve remain controversial. Recent advancements in surgical techniques may challenge the previously established evidence regarding the detrimental effects of surgery …
Comparison of quality of life in patients with endometriosis undergoing treatment with progestins, oral contraceptives pills (OCP), and GnRH agonists.
The objective of this study was to compare the quality of life in patients with endometriosis undergoing treatment with progestins, OCPs, and GnRH agonists.
Anti‑inflammatory and anti‑migratory properties of wild‑grape‑derived ε‑viniferin in human endometrial cells: A potential therapy for endometriosis.
Endometriosis is a chronic gynecological disorder characterized by the ectopic growth and proliferation of endometrial tissue outside the uterine cavity, leading to inflammation. Although low‑dose contraceptive pills are widely used …